Premium
Suspected piperacillin‐tazobactam induced nephrotoxicity in the pediatric oncology population
Author(s) -
Pratt Jennifer A.,
Stricherz Melisa K.,
Verghese Priya S.,
Burke Michael J.
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24720
Subject(s) - medicine , neutropenia , nephrotoxicity , piperacillin/tazobactam , febrile neutropenia , pediatric cancer , empiric therapy , piperacillin , acute kidney injury , population , tazobactam , complication , intensive care medicine , cancer , chemotherapy , pathology , kidney , pseudomonas aeruginosa , genetics , alternative medicine , environmental health , biology , bacteria
Abstract Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin‐tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with pediatric malignancies admitted to the hospital and treated for fever ± neutropenia. All patients exhibited acute renal injury shortly after PIP/TAZO administration with one of these cases having biopsy evidence of acute interstitial nephritis. These findings are suggestive of PIP/TAZO induced nephrotoxicity in pediatric oncology patients with fever ± neutropenia and that PIP/TAZO should be used judiciously in this population. Pediatr Blood Cancer 2014;61:366–368. © 2013 Wiley Periodicals, Inc.